¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell adhesive matrix assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • acidophilic cell
    È£»ê¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷, ¼¼¿±¼¼Æ÷
  • acinar cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • adult T-cell leukemia/lymphoma
    ¼ºÀÎT¼¼Æ÷¹éÇ÷º´/¸²ÇÁÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • anaplastic large cell lymphoma
    ¿ªÇü¼ºÅ«¼¼Æ÷¸²ÇÁÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • transitional cell
    ÀÌÇ༼Æ÷
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • nail matrix
    ¼Õ¹ßÅé¹ÙÅÁÁú
  • organic matrix
    À¯±â¹ÙÅÁÁú
  • similarity matrix
    Çà·Ä½ÄÀ¯»çµµ°Ë»ç
  • spring fixed matrix
    ź·Â°íÁ¤´ë»ó°Ýº®
  • territorial matrix
    ¿µ¿ª¹ÙÅÁÁú
  • variance matrix
    ºÐ»êÇà·Ä
  • acantholytic cell
    °¡½Ã¼¼Æ÷ÇØ¸®¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • receptor assay
    ¼ö¿ëÃ¼ÃøÁ¤
  • NK cell [=natural killer cell]
    ÀÚ¿¬»ì»ó¼¼Æ÷
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • quiescent cell, Q cell
    Á¤Áö¼¼Æ÷
  • A cell
    A ¼¼Æ÷
  • B cell
    B¼¼Æ÷(~ á¬øà)
  • B cell
    B ¼¼Æ÷
  • B cell
    B ¼¼Æ÷.
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
  • B cell differentiation factor (BCDF)
    B¼¼Æ÷ ºÐÈ­À¯¹ßÀÎÀÚ
  • B cell growth factor
    B ¼¼Æ÷¼ºÀåÀÎÀÚ
  • B cell growth factor (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • B cell hybridoma
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • B cell lymphoma
    B¼¼Æ÷¸²ÇÁÁ¾
  • B cell stimulating factor (BSF)
    B¼¼Æ÷ ÀÚ±ØÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • mesangial matrix
    Ç÷°ü»çÀ̱âÁú, Ç÷°ü°£±âÁú (¡­Ñ¨òõ).
  • mitochondrial matrix
    »ç¸³Ã¼±âÁú(Þêí£ô÷Ðñòõ).
  • mitochondrial matrix
    »ç¸³Ã¼¹ÙÅÁÁú
  • nail bed ³ª matrix unguis
    ¼ÕÅé¹Ù´Ú, Á¶»ó(ðÐßÉ).
  • nail bed ³ª matrix unguis
    ¼ÕÅé¹Ù´Ú,Á¶»ó
  • nail matrix
    ¼ÕÅé±âÁú, Á¶±âÁú(ðÐÐñòõ), Á¶¸ð.
  • nail matrix
    ¹ßÅé¹ÙÅÁÁú
  • nail matrix
    ¼ÕÅé¹ÙÅÁÁú
  • organic matrix
    À¯±â±âÁú(êóѦÐñòõ).
  • similarity matrix
    Çà·Ä½Ä À¯»çµµ°Ë»ç
  • spring fixed matrix
    ź·Â°íÁ¤´ë»ó°Ýº®(÷¥æ³ ͳïÒÓáßÒ̰Ûú).
  • territorial matrix
    ¿µ¿ª¹ÙÅÁÁú
  • variance matrix
    ºÐ»êÇà·Ä.
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • acid phosphatase assay
    »ê¼ºÆ÷½ºÆÄŸÁ¦ ÃøÁ¤
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Multinuclear giant cell
    ¹µÇÙ°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÙÇÙ¼º°Å´ë¿µ¾ç¸·¼¼Æ÷
  • Taste cell
    ¹Ì°¢¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì°¢¼¼Æ÷
  • Undifferentiated cell
    ¹ÌºÐÈ­¼¼Æ÷
    [¿¾ ¿ë¾î] ¹ÌºÐÈ­¼¼Æ÷
  • Microvillous epithelial cell
    ¹Ì¼¼À¶¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ð»óÇǼ¼Æ÷
  • Microvillous cuboidal mesothelial cell
    ¹Ì¼¼À¶¸ðÀÔ¹æÁßÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ðÀÔ¹æÁßÇǼ¼Æ÷
  • Microplica epithelial cell
    ¹Ì¼¼ÁÖ¸§»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼ÁÖ¸§»óÇǼ¼Æ÷
  • Nonfenestrated endothelial cell
    ¹Îâ³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹«Ã¢³»ÇǼ¼Æ÷
  • Basket cell
    ¹Ù±¸´Ï¼¼Æ÷
    [¿¾ ¿ë¾î] ³ó¼¼Æ÷
  • Outer pillar cell
    ¹Ù±ù±âµÕ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁÖ¼¼Æ÷
  • Outer sustentacular cell
    ¹Ù±ù¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁöÁÖ¼¼Æ÷
  • Outer phalangeal cell of Deiters
    ¹Ù±ù¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁö»ó¼¼Æ÷
  • Outer hair cell
    ¹Ù±ùÅм¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÀ¯¸ð¼¼Æ÷
  • Basal epithelial cell
    ¹Ù´Ú»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±âÀúÃþ»óÇǼ¼Æ÷
  • Basal cell
    ¹Ù´Ú¼¼Æ÷
    [¿¾ ¿ë¾î] ±âÀú¼¼Æ÷
  • Fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó±Ù»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • competent cell
    Àû°Ý¼¼Æ÷(îêÌ«á¬øà)
  • constitutive secretory cell
    ±¸¼º¼º ºÐºñ¼¼Æ÷(ϰà÷àõÝÂÝôá¬øà)
  • continuous cell line
    "Áö¼Ó¼¼Æ÷ÁÖ(ò¥áÙá¬øàñ»), (ÔÒ) established cell line"
  • COS cell
    COS ¼¼Æ÷(á¬øà)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • double-sector cell
    ÀÌÁß±¸È¹½Ç(ì£ñìÏ¡üñãø)
  • effector cell
    È¿°ú±â ¼¼Æ÷(üùÍýÐïá¬øà)
  • enucleated cell
    Á¦ÇÙ ¼¼Æ÷ (ð¶ú·á¬øà)
  • established cell line
    ¼ö¸³ ¼¼Æ÷ÁÖ (â§Ø¡á¬øàñ»)
  • feeder cell
    °ø±ÞÀÚ¼¼Æ÷ (ÍêÐåíºá¬øà)
  • flow cell
    È帧 ½Ç(ãø)
  • founder cell
    ½ÃÁ¶ ¼¼Æ÷(ã·ðÓá¬øà)
  • germ cell
    ¹è¼¼Æ÷(ÛÏá¬øà)
  • germinal cell
    ¹è¾Æ¼¼Æ÷(ÛÏä´á¬øà)
  • glial cell
    ½Å°æ±³¼¼Æ÷(ãêÌèÎïá¬øà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • signet-ring cell
    ¹ÝÁö¼¼Æ÷, ÀÎȯ¼¼Æ÷
  • small cell
    ¼Ò¼¼Æ÷
  • small cleaved cell
    ¼ÒºÐÇÒ¼¼Æ÷
  • spindle cell
    ¹æÃ߻󼼯÷
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • stem cell
    °£¼¼Æ÷
  • stromal cell
    °£Áú¼¼Æ÷
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • white blood cell
    ¹éÇ÷±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MP macrophage; matrix protein; mean pressure; melphalan and prednisone; melting point; membrane potenti...
MX matrix
PPMS Performax's Personal Matrix System
RAM random-access memory; rapid alternating movements; rectus abdominis muscle; rectus abdominis myocuta...
RAM-FAST reduced acquisition matrix-Fourier acquired steady state
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MA Matrix
MALDIMS Matrix Assisted Laser Desorption Ionisation Mass Spectrometry
MALDI-TOF MS Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry
MALDI Matrix Assisted Laser Desorption/Ionization
MAR matrix associated region
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adipose cell
    Áö¹æ ¼¼Æ÷
    Áö¹æÀ» °¡Áø ¼¼Æ÷·Î¼­ ¼¼Æ÷´Â ±¸ÇüÀ» ÀÌ·ç°í, ÇÙÀº ÇÑ ÂÊÀ¸·Î Ä¡¿ìÃÄ ÀÖ´Ù.
  • adrenal medullary chromaffin cell
    ºÎ½Å ¼öÁú Å©·Ò ģȭ ¼¼Æ÷
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • air cell
    ÇԱ⠼¼Æ÷
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • Alzheimer's cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • angiotropic intravascular large cell lymphoma
    Ç÷°ü ¿µ¾ç¼º Ç÷°ü³» ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
checkerboard assay <procedure> Variant of the Boyden chamber assay for leucocyte chemotaxis introduced by Zigmond. By testing different concentrations of putative chemotactic factor in nongradient conditions, it is possible to calculate the enhancement of movement expected due simply to chemokinesis and to compare this with the distances moved in positive and negative gradients. Good experimental design thus allows chemotaxis to be distinguished from chemokinesis.
(21 May 1997)
chloramphenicol acetyltransferase assay <investigation> A lab technique used to determine whether a given fragment of DNA has a promoter on it to encourage transcription to occur, by attaching the gene (called the CAT gene) which codes for the CAT enzyme to it, and observing whether the CAT enzyme is produced.
(05 Jan 1998)
Grunstein-Hogness assay A procedure for identifying plasmid clones by colony hybridization.
(05 Mar 2000)
christmas factor assay A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
clonogenic assay In vitro culturing of neoplastic cells to test their radiosensitivity or chemosensitivity, and probable clinical efficacy of a therapeutic agent.
(05 Mar 2000)
colony-forming units assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
(12 Dec 1998)
competitive binding assay General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plaque assay 1. <investigation> Assay for virus in which a dilute solution of the virus is applied to a culture dish containing a layer of the host cells, convective spread is prevented by making the medium very viscous. After incubation the plaques, areas in which cells have been killed (or transformed), can be recognised and the number of infective virus particles in the original suspension estimated.
2. Assay for cells producing antibody against erythrocytes or against antigen that has been bound to the erythrocytes. The cell is surrounded by a clear plaque of haemolysis. Basic principle behind the assay is the same as for the virus plaque assay.
(18 Nov 1997)
haemolytic plaque assay <investigation> A haemolytic plaque assay is a lab technique used to show that certain antibodies are secreted by antibody-making cells when these cells are mixed with red blood cells.
The mixture is spread onto a plate of agar, if a plaque appears, it means that the red blood cells have been destroyed (by haemolysis) by the antibodies.
(09 Oct 1997)
Hageman factor assay A test used to measure the activity of a blood clotting factor XII. This test may be used to evaluate excessive bleeding. Low factor XII may be seen in cases of congenital deficiency of factor XII, heparin administration and liver disease.
(27 Sep 1997)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
hemizona assay <investigation> The hemizona assay is a laboratory test of the ability of sperm to penetrate into a human egg, first the egg is split in half, then one half is tested against the husband's sperm and the other half against sperm from a fertile man.
(09 Oct 1997)
scintillation proximity assay Assay system in which antibody or receptor molecule is bound to a bead that will emit light when _ emission from an isotope occurs in close proximity, i.e. From a radioactively labelled ligand. Avoids the need for scintillant in order to measure the amount of bound isotope and thus the amount of antigen or ligand present.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á